Publication date: Jun 18, 2024

While increasing evidence supports the safety and effectiveness of immunohistochemistry-assisted Mohs micrographic surgery (MMS) for superficially invasive melanoma, there is a paucity of the literature investigating its effect on final defect size. To evaluate the tissue sparing effect of MMS for melanoma. Three hundred and twenty-eight patients with early-stage (T1a/T1b) cutaneous melanomas treated with MMS from January 2008 to December 2018 were evaluated. Measured defect sizes after Mohs tumor extirpation were compared with anticipated defect size that would result from standard-margin wide local excision (WLE). Average actual versus anticipated defect areas were compared using a paired t-test (95% confidence intervals). The following groups demonstrated a significantly smaller defect area for MMS-treated tumors when compared with anticipated standard-margin WLE defect: All tumors combined (13. 8 cm2 vs 10. 4 cm2, p < .001), tumors requiring 1 stage (13. 6 cm2 vs 10. 1 cm2,p < .001), and tumors requiring 2 stages (13. 2 cm2 vs 10. 5 cm2, p = .004). The majority of patients (83. 5%, n = 274) achieved clear margins with 1 stage. Immunohistochemistry-assisted MMS for early-stage invasive melanoma is associated with smaller final defect size and overall tissue sparing effect compared with standard WLE margins.

Semantics

Original Article